20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency

Ann Allergy Asthma Immunol. 2016 Jul;117(1):93-4. doi: 10.1016/j.anai.2016.04.023. Epub 2016 May 26.

Authors

Richard L Wasserman¹, Mark R Stein², M Elizabeth M Younger³, Shahnaz Fatteh⁴, Elie Haddad⁵

Affiliations

¹ Allergy Partners of North Texas Research, Dallas, Texas. Electronic address: [email protected].
² Allergy Associates of the Palm Beaches, North Palm Beach, Florida.
³ Johns Hopkins University School of Medicine, Baltimore, Maryland.
⁴ Larkin Community Hospital, South Miami, Florida.
⁵ Department of Pediatrics and Department of Microbiology, Infectiology and Immunology, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada.

PMID: 27236217
DOI: 10.1016/j.anai.2016.04.023

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Child
Drug Approval
Female
Humans
Immunoglobulins / therapeutic use*
Immunologic Deficiency Syndromes / immunology
Immunologic Deficiency Syndromes / therapy*
Immunotherapy / methods*
Injections, Subcutaneous
Male
Middle Aged
Retrospective Studies
Treatment Outcome
Young Adult

Substances

Immunoglobulins